Ticker
$KRRO
1 catalyst touching KRRO in the last 60 days, newest first, each with the price move that followed.
- 72
Korro Bio doses first cohort in Phase 1/2 trial of KRRO-121
Korro Bio announced first-in-human dosing of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide, in its ANCHOR Phase 1/2 trial for hyperammonemia and hepatic encephalopathy. Clinical trial initiation marks a material milestone for a lead program, signaling progress toward potential regulatory path and reducing development risk for the company.
KRRO ▲SEC 8-K · 5 Oct 2026, 20:10 UTC
Information only. AURA does not give buy or sell recommendations.